Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops

Chinese Journal of Ophthalmology

Volumn 42, Issue 7, 2006, Pages 637-641

  Zhang, Jun Jie ^a   Gao, Chang Feng ^a   Wang, L Y ^a  

^a HENAN INSTITUTE OF OPHTHALMOLOGY   (China)

Author keywords

Aqueous humor; Chromatography, high pressure liquid; Cornea; Ganciclovir; Ophthalmic solutions; Pharmacokinetics

Indexed keywords

EYE DROPS; GANCICLOVIR;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CORNEA; DISSECTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; LACRIMAL FLUID; LACRIMAL FLUID LEVEL; NONHUMAN; RABBIT; RANDOMIZATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STATISTICAL ANALYSIS; STUDENT T TEST; TISSUE PRESERVATION;

ANIMALS; ANTIVIRAL AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CORNEA; FEMALE; GANCICLOVIR; MALE; OPHTHALMIC SOLUTIONS; RABBITS; RANDOM ALLOCATION; TEARS;

EID: 33748666866     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Colin J, Hoh HB, Easty DL, et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea, 1997, 16:393-399.
2. Smee DF, Martin JC, Verheyden JP, et al. Antiherpesvirus avtivity of the acylic nuleoside 9-(1,3-dihydroxy-2-propoxymethyl) guanine. Antimicrob Agents Chemother, 1983, 23:676-682.
3. Shiota H, Naito T, Mimura Y. Anti-herpes simplex virus (HSV) effect of 9-(1.3-dihydroxy-2-propoxymethyl) guanine (DHPG) in rabbit cornea. Curr Eye Res, 1987, 6:241-245.
4. Simth KO, Hodges SL, Kermell WL, et al. Experimental ocular herpetic infections in rabbits: treatment with 9-[2-hydroxy-1-(hydroxymethyl) ethoxy] methyl guanine. Arch Ophthalmol, 1984, 102:778-781.
5. Trousdale MD, Nesburn AB, Willey DU, et al. Efficacy of BW759 9-[2-hydroxy-1-(hydroxymethyl) ethoxy] methyl guanine against herpes simplex virus type 1 keratitis in rabbits. Curr Eye Res, 1984, 3:1007-1015.
6. Tirucherai GS, Dias C, Mitra AK. Comeal permeation of ganciclovir: mechanism if ganciclovir permeation enhencement by acyl ester prodrug design. J Ocul Pharmacol Ther, 2002, 18: 535-548.
7. Castela N, Vermerie N, Chast F, et al. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. J Ocul Pharmacol Ther, 1994, 10:439-451.
8. Fresta M, Fontana G, Bucolo C, et al. Ocular tolerability and in vivo bioavaibility of poly(ethylene glycol) (PEG) - coated polythyl-2-cyanoacrylate nanospheres-encapsulated acyclovir. J Pharm Sci, 2001, 90:288-297.
9. Hoh HB, Hurley C, Claoue C, et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol, 1996, 80:140-143.
10. Maurice DM, Srinivas SP. Use of fluorometry in assessing the efficacy of a cation-sensitive gel as an ophthalmic vehicle: comparison with scintigraphy. J Pharm Sci, 1992, 81: 615-619.
11. Wilson CG, Zhu YP, Frier M, et al. Ocular contact time of a carbomer gel (GelTears) in humans. Br J Ophthalmol, 1998, 82: 1131-1134.